glp-1 drugs and multiple sclerosis Episode 444: A Drug for MS? with Dr. Ellen Mowry glp 1 for ms patients
Description
Curious about microdosing GLP-1s
The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.
Discover how GLP-1 medications help fatty liver disease through clinical evidence, FDA-approved options, patient selection criteria, and monitoring protocols for MASLD and NASH treatment.
Packaging and label may vary
One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach
Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma
